Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

MVM Raising £40M To Invest In Young U.S., UK Companies

Feb. 28, 2001

Xenova, Cantab Merging Via All-Stock Deal Valued At £124

Feb. 21, 2001

Cyclacel Moves Oral CDK Inhibitor Into Human Trials

Feb. 21, 2001

Pharming Completes Study, Enters Deal With AM-Pharma

Feb. 21, 2001

Cyclacel Moves Oral CDK Inhibitor Into Human Trials

Feb. 21, 2001

Xenova, Cantab Merging Via All-Stock Deal Valued At £124

Feb. 21, 2001

Pharming Completes Study, Enters Deal With AM-Pharma

Feb. 21, 2001

HUPO Formed To Capitalize On Genome, Advance Proteomics

Feb. 20, 2001

HUPO Formed To Capitalize On Genome, Advance Proteomics

Feb. 20, 2001

KS Biomedix Moves Lead Drug Into Phase IIb, Eyes Pivotal Trial

Feb. 14, 2001

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...